About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MaxCyte, Inc. - Common Stock (NQ:MXCT)

0.6896 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MaxCyte, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Planned CFO Transition in 2026
Company initiates search for successor 
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
MaxCyte’s Flow Electroporation® Technology will support efficient gene delivery to advance Moonlight Bio’s engineered T cell therapies 
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Signs Platform License Agreement with Adicet Bio
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapies 
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines 
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for... 
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference
From MaxCyte, Inc
Via GlobeNewswire
News headline image
Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Retirement of Board Member Art Mandell
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
Since 1999, MaxCyte’s non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects 
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Participate in Two Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Appoints Cynthia Collins to its Board of Directors
From MaxCyte, Inc
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.